Rezolute

Rezolute is a late-stage rare disease biopharmaceutical company headquartered in Redwood City, California that is developing ersodetug, a novel treatment for severe hypoglycemia caused by congenital and tumor hyperinsulinism (HI) — a life-threatening condition with no approved therapies. The company has two Phase 3 clinical programs underway targeting both congenital HI and tumor HI, with compelling outcomes from an Expanded Access Program, and its mission is to substantially improve quality of life for patients by eliminating the burden of unpredictable, life-threatening hypoglycemic episodes. Rezolute's customers are rare disease patients, their families, and the clinicians who treat hyperinsulinism disorders, a historically underserved population with high unmet medical need.